HomeCancer diagnoses dropped sharply in Alberta during COVID-19 response

Cancer diagnoses dropped sharply in Alberta during COVID-19 response

Published on

Pandemic restrictions corresponded with a significant drop in diagnoses of breast, colorectal and prostate cancers as well as melanoma, according to a new Alberta study published in CMAJ (Canadian Medical Association Journal).

“The sweeping and unprecedented measures enacted at the beginning of the COVID-19 pandemic in Alberta had an inevitable impact on cancer care,” writes Dr. Darren Brenner, an epidemiologist in Calgary, Alberta, and associate professor at the University of Calgary’s Cumming School of Medicine, with coauthors. “Even though treatment and urgent surgeries for cancers were prioritized when other procedures were delayed or cancelled, preventive and diagnostic services were greatly reduced.”

The study compared survival rates for 3 groups of patients diagnosed between (1) Jan. 16, 2018, and Mar. 15, 2019; (2) Mar. 16, 2019, and Mar. 15, 2020; and (3) Mar. 16 and Dec. 15, 2020. The researchers divided the third period into a “state of emergency” (SOE) phase (Mar. 16 to June 15, 2020) and post-SOE phase (June 16 to Dec. 15, 2020).

Researchers saw large reductions in the number of new diagnoses for some cancer types during the SOE period, with a drop of 43 per cent (melanoma), 36 per cent (colorectal and prostate) and 33 per cent (breast). In the post-SOE phase, diagnoses increased nine per cent, eight per cent and 10 per cent per month, respectively. Other cancers, such as bladder, kidney, lung and cervical, did not show decreases in diagnoses during that period.

“Our findings that early-stage breast and colorectal cancer had the largest decrease in diagnoses suggest that a reduction in screening services during the first wave of pandemic-related restrictions in Alberta resulted in asymptomatic individuals receiving a diagnosis later than they would have otherwise,” write the authors. “These results highlight the importance of screening services in reducing late-stage cancer diagnoses.”

Patients with colorectal cancer and non-Hodgkin lymphoma diagnosed during the pandemic period in 2020 had poorer one-year survival than those diagnosed in 2018. 

By December 2020, the rate of diagnoses had returned to a level more in line with pre-SOE levels.

The findings are consistent with studies from the United Kingdom, United States, the Netherlands, Germany, Japan and other parts of Canada. In Ontario, there was a 34 per cent drop in new cancer diagnoses in April 2020, and Manitoba had a 23 per cent reduction in the same period. An estimated 15 per cent reduction in Quebec occurred in the first year of the pandemic.

Cancer care must become more efficient and increase capacity to reduce long-term effects of the pandemic on cancer outcomes, the authors conclude.

“Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta” was published June 12, 2023.

Latest articles

The Cost of Silence: Why Black Youth Mental Health Can’t Wait

When we talk about mental health in Canada, the general numbers often hide a...

Iron deficiency anemia – demystifying a common, treatable and preventable public health problem

Over 830,000 Canadians have iron deficiency anemia (IDA),1 the most common cause of anemia.2...

Women living with Parkinson’s are overlooked and under-researched

Nearly half of Parkinson’s diagnoses are women, yet their care, support and research is...

Antibiotic resistance in Canada: What you can do

It’s normal to want quick relief when you’re sick fighting an infection. Antibiotics seem...

More like this

A new home for Canada’s largest Cancer Research Tumour Bank

Decades of cancer research — and thousands of patient tumour samples — now have...

Equity-focused study on immigrant kidney disease risk

HN Summary • A new SHN-led study published in BMJ Open reveals significant disparities in...

Shorter duration of antimicrobial therapy in common infections

HN Summary • Growing evidence shows that shorter courses of antibiotics are just as effective...

Global clinical trial exploring potential treatment for sickle cell disease

HN Summary • SHN is leading a global clinical trial testing tebapivat, an investigational oral...

Lithium study yields insights in the fight against HIV

Study in human cells finds low-cost drug keeps virus dormant through an unexpected pathway,...

Gene mutation in blood-forming cells may improve cancer immunotherapy results

Researchers at UHN’s Princess Margaret Cancer Centre have found that inactivation of the TET2...